Antibodies or antigen-binding fragments that bind to monkeypox virus and their applications
Monoclonal antibodies against monkeypox virus A29L, A35R, and M1R proteins were obtained by immunizing New Zealand rabbits. This solved the problems of weak affinity and poor specificity of monkeypox virus monoclonal antibodies in existing technologies, and developed a highly efficient rapid detection product for monkeypox virus, achieving high sensitivity and specificity for the detection of monkeypox virus.
Patent Information
- Application Number
- CN202211185655.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-27
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-09-27
AI Technical Summary
Existing monkeypox virus monoclonal antibodies suffer from weak affinity and poor specificity, and the development of rapid detection products for monkeypox virus antigens depends on high-quality monkeypox virus monoclonal antibodies. Currently, there is a lack of effective rapid diagnostic methods.
A series of monoclonal antibodies were obtained by immunizing New Zealand rabbits with monkeypox virus A29L, A35R and M1R proteins. The CDR region sequence was determined by cloning and gene structure analysis, and antibodies or antigen-binding fragments with specific CDR composition that bind to monkeypox virus were developed.
It provides a high-affinity and high-specificity monkeypox virus monoclonal antibody, which improves the sensitivity and specificity of monkeypox virus detection. It is suitable for monkeypox virus antigen detection and identification of infected clinical samples, and has important application value.
Smart Images

Figure CN115925885B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of antibody technology, and in particular to an antibody or antigen-binding fragment thereof that binds to monkeypox virus and its applications. Background Technology
[0002] Monkeypox is a viral zoonotic disease caused by the monkeypox virus. It is transmitted from animals to humans through close contact, through close contact with contaminated materials, and also from person to person. Monkeypox was first discovered in 1958 in monkey populations used for research and is commonly found in virus-carrying animals in the rainforests of Central and West Africa. Currently, the monkeypox virus is spreading across geographical boundaries of natural foci worldwide, becoming the most important extant orthopox virus-related infectious disease since the eradication of smallpox. There have been 41,000 confirmed cases and 12 deaths in 96 countries and regions, and the number is increasing exponentially. Currently, there are no clinically validated effective drugs against monkeypox. Early diagnosis of monkeypox is crucial for effectively curbing its spread.
[0003] Monkeypox virus (MPV) is an enveloped double-stranded DNA virus with two infectious forms: extracellular enveloped virus (EV) and mature intracellular virus (MV). MV is the most abundant and stable form in the environment, and is the main form of viral transmission between hosts. More than 20 structural proteins have been identified, including A29L, a membrane protein of MPV MV, which binds to glycosaminoglycans on the cell surface and mediates virus-cell fusion; M1R, another membrane protein of MV, is highly conserved among known poxviruses; and A35R, an envelope glycoprotein on the surface of EV, can induce the production of neutralizing antibodies, blocking viral transmission between cells. These proteins are considered important targets for MPV research.
[0004] Currently, monoclonal antibodies are typically prepared using hybridoma technology. This technology, based on cell fusion techniques, fuses sensitized B cells capable of secreting specific antibodies with myeloma cells capable of unlimited proliferation to create a B-cell hybridoma. A single hybridoma cell with these characteristics is then cultured into a cell population to produce a specific antibody against a single antigenic epitope, i.e., a monoclonal antibody. Currently, the most widely used monoclonal antibodies are murine monoclonal antibodies; however, murine monoclonal antibodies suffer from weak affinity and poor specificity. Similarly, the preparation of monkeypox virus monoclonal antibodies also faces these problems.
[0005] The 2022 guidelines for monkeypox diagnosis and treatment include nucleic acid testing and viral culture for pathogen detection, which suffers from long testing cycles. The development of rapid monkeypox virus antigen detection products would enable rapid screening during a pandemic, allowing for quick, accurate, and safe initial screening of large populations, including suspected cases, asymptomatic infections in the incubation period, and higher-risk asymptomatic carriers. However, the development of rapid diagnostic products relies on high-quality monkeypox virus monoclonal antibodies. Therefore, improving monkeypox virus monoclonal antibodies is a pressing issue that needs to be addressed.
[0006] In view of this, the present invention is hereby proposed. Summary of the Invention
[0007] This invention relates to a series of monoclonal antibodies obtained by immunizing New Zealand rabbits with monkeypox virus A29L, A35R, and M1R proteins. Through cloning, identification, and gene structure analysis, the CDR region sequence of each antibody was determined, resulting in a series of antibodies or antigen-binding fragments of monkeypox virus with specific CDR compositions. Based on these antibodies or antigen-binding fragments, this invention also provides related biomaterials, products, and applications.
[0008] To solve the above-mentioned technical problems, the present invention adopts the following technical solution:
[0009] According to one aspect of the present invention, an antibody or antigen-binding fragment thereof that binds to monkeypox virus is provided, said antibody or antigen-binding fragment having a heavy chain variable region and a light chain variable region;
[0010] The heavy chain variable region includes three complementary determinant regions CDR-H1, CDR-H2 and CDR-H3;
[0011] The light chain variable region includes three complementary determinant regions CDR-L1, CDR-L2 and CDR-L3;
[0012] The antibody or its antigen-binding fragment is selected from (a), (b), or (c):
[0013] (a) An antibody or its antigen-binding fragment Anti-MPXV-A29L-1 or Anti-MPXV-A29L-2 that binds to the monkeypox virus A29L protein;
[0014] The amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of Anti-MPXV-A29L-1 are shown in Seq_1, Seq_2 and Seq_3, respectively; the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 are shown in Seq_4, Seq_5 and Seq_6, respectively.
[0015] The amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 of Anti-MPXV-A29L-2 are shown in Seq_11, Seq_12, and Seq_13, respectively; the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown in Seq_14, Seq_15, and Seq_16, respectively.
[0016] (b) An antibody or its antigen-binding fragment Anti-MPXV-A35R-1 or Anti-MPXV-A35R-2 that binds to the monkeypox virus A35R protein;
[0017] The amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 of Anti-MPXV-A35R-1 are shown in Seq_21, Seq_22, and Seq_23, respectively; the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown in Seq_24, Seq_25, and Seq_26, respectively.
[0018] The amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 of Anti-MPXV-A35R-2 are shown in Seq_31, Seq_32, and Seq_33, respectively; the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown in Seq_34, Seq_35, and Seq_36, respectively.
[0019] (c) An antibody or its antigen-binding fragment Anti-MPXV-M1R-1 or Anti-MPXV-M1R-2 that binds to the monkeypox virus M1R protein;
[0020] The amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 of Anti-MPXV-M1R-1 are shown in Seq_41, Seq_42, and Seq_43, respectively; the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown in Seq_44, Seq_45, and Seq_46, respectively.
[0021] The amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of Anti-MPXV-M1R-2 are shown in Seq_51, Seq_52 and Seq_53, respectively; the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 are shown in Seq_54, Seq_55 and Seq_56, respectively.
[0022] According to another aspect of the invention, the invention also provides a biological material related to the antibody or antigen-binding fragment thereof that binds to monkeypox virus as described above.
[0023] According to another aspect of the invention, the invention also provides a composition for tracing, the composition comprising the antibody or antigen-binding fragment thereof that binds to monkeypox virus and a marker; said marker comprising one or more of enzymes, fluorescent molecular markers, fluorescent microspheres, colored microspheres, colloidal gold, biotin, or streptavidin.
[0024] According to another aspect of the present invention, the present invention also provides a composition for detecting monkeypox virus, the composition comprising at least one of an A29L protein-pairing antibody or an antigen-binding fragment thereof, an A35R protein-pairing antibody or an antigen-binding fragment thereof, and an M1R protein-pairing antibody or an antigen-binding fragment thereof; wherein the A29L protein-pairing antibody or an antigen-binding fragment thereof is composed of Anti-MPXV-A29L-1 and Anti-MPXV-A29L-2; the A35R protein-pairing antibody or an antigen-binding fragment thereof is composed of Anti-MPXV-A35R-1 and Anti-MPXV-A35R-2; and the M1R protein-pairing antibody or an antigen-binding fragment thereof is composed of Anti-MPXV-M1R-1 and Anti-MPXV-M1R-2.
[0025] According to another aspect of the invention, the invention also provides the use of the above-described antibody or antigen-binding fragment thereof that binds to monkeypox virus, the above-described biological material, the above-described tracing composition, and the above-described composition for detecting monkeypox virus in the preparation of products for detecting monkeypox virus A29L protein, monkeypox virus A35R protein, monkeypox virus M1R protein, or monkeypox virus.
[0026] According to another aspect of the present invention, the present invention also provides a reagent or kit for detecting monkeypox virus, the kit comprising the above-described antibody or antigen-binding fragment thereof that binds to monkeypox virus, the above-described tracing composition, or the above-described composition for detecting monkeypox virus.
[0027] According to another aspect of the invention, the invention also provides a medicament for the prevention or treatment of monkeypox, the medicament comprising the antibody or antigen-binding fragment thereof that binds to the monkeypox virus, or the aforementioned biological material; and pharmaceutically optional excipients.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The present invention provides a series of antibodies or antigen-binding fragments against monkeypox virus, which have heavy chain variable regions and light chain variable regions, each including three complementarity-determining regions (CDRs). The CDR sequences of the antibodies or antigen-binding fragments provided by the present invention are derived from rabbits.
[0030] Monoclonal antibodies are highly homogeneous antibodies produced by a single B cell clone that target only a specific antigenic epitope. Sequence analysis of monoclonal antibodies can reveal the CDR sequence, which plays a major role in the antibody's binding specificity and affinity.
[0031] Currently, the most common method for preparing monoclonal antibodies or obtaining CDR sequences is to immunize mice to prepare murine monoclonal antibodies and then obtain murine CDR sequences. However, murine monoclonal antibodies suffer from weak affinity and poor specificity. Compared to murine monoclonal antibodies, rabbit monoclonal antibodies can recognize more antigen-binding sites and have the characteristics of high affinity and high specificity.
[0032] This invention relates to a series of monoclonal antibodies obtained by immunizing New Zealand rabbits with monkeypox virus A29L, A35R, and M1R proteins. Through cloning, identification, and gene structure analysis, the CDR region sequences of each antibody were determined. This invention uses New Zealand rabbits as the experimental animal to prepare monoclonal antibodies, overcoming the shortcomings of weak affinity and low specificity of antibodies or antigen-binding fragments composed of mouse CDRs. This invention uses recombinant antigens of monkeypox virus membrane proteins A29L, A35R, and M1R for immunization. The resulting spleen cells are then fused with myeloma cells to obtain rabbit-derived antibodies or antigen-binding fragments with specific CDR compositions. Antibodies or antigen-binding fragments with specific CDR compositions provided by this invention have the advantages of good stability, strong affinity for monkeypox, and multiple recognition sites.
[0033] High-performance antibodies are the foundation of immunological detection; only with high-performance antibodies can high-performance detection kits be developed. Validation has shown that three pairs of monkeypox virus antibodies or their antigen-binding fragments possess multiple antigen recognition sites, high specificity, high affinity, and structural stability. Applying these antibodies or their antigen-binding fragments to the development of immunodiagnostic reagents can improve the sensitivity and specificity of serological methods for detecting monkeypox antigens. This has significant application value in the preparation of products for monkeypox virus detection and can potentially be used in the preparation of products for antigen detection of monkeypox virus and the detection and identification of clinical samples infected with monkeypox. Attached Figure Description
[0034] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0035] Figure 1 Electrophoresis image of anti-monkeypox virus monoclonal antibody;
[0036] Figure 2 For the determination of the potency of Anti-MPXV-A29L-1;
[0037] Figure 3 For the determination of the potency of Anti-MPXV-A29L-2;
[0038] Figure 4 For the determination of the potency of Anti-MPXV-A35R-1;
[0039] Figure 5 For the determination of the potency of Anti-MPXV-A35R-2;
[0040] Figure 6 For the determination of Anti-MPXV-M1R-1 potency;
[0041] Figure 7 For the determination of the potency of Anti-MPXV-M1R-2. Detailed Implementation
[0042] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0043] Generally, the nomenclature and techniques used in cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization, together with those described herein, are those well-known and commonly used in the art. Unless otherwise stated, the methods and techniques of the present invention are generally carried out according to conventional methods well-known in the art and described in various general and more specific references, which are cited and discussed throughout this specification. Enzymatic reactions and purification techniques are carried out according to the manufacturer's instructions, as commonly practiced in the art, or as described herein. The nomenclature, laboratory procedures, and techniques used in analytical chemistry, synthetic organic chemistry, and medical and medicinal chemistry, together with those described herein, are those well-known and commonly used in the art.
[0044] According to one aspect of the present invention, an antibody or antigen-binding fragment thereof that binds to monkeypox virus is provided, said antibody or antigen-binding fragment having a heavy chain variable region and a light chain variable region; the heavy chain variable region includes three complementarity-determining regions CDR-H1, CDR-H2 and CDR-H3; the light chain variable region includes three complementarity-determining regions CDR-L1, CDR-L2 and CDR-L3.
[0045] This invention is based on the monoclonal antibodies obtained by immunizing rabbits with the A29L, A35R, and M1R proteins from the mature intracellular virion of monkeypox virus. Through cloning, identification, and gene structure analysis, the CDR region sequences of each monoclonal antibody were determined, and antibodies or antigen-binding fragments with the following CDR sequences were obtained.
[0046] Anti-MPXV-A29L-1
[0047] In some alternative implementations, after immunizing rabbits with monkeypox virus A29L protein, screening and sequence analysis yielded antibodies or antigen-binding fragments thereof that bind to monkeypox virus A29L protein, having the following CDR composition: Anti-MPXV-A29L-1.
[0048] Heavy chain variable region:
[0049] The heavy chain variable region has a heavy chain CDR composed of CDR-H1, CDR-H2, and CDR-H3, and the amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 are shown below:
[0050] CDR-H1: RGYYWS(Seq_1);
[0051] CDR-H2:YISNSESVNYNPSLKS(Seq_2);
[0052] CDR-H3:GYECKIPSGLDS(Seq_3).
[0053] The preferred amino acid sequence of the heavy chain variable region containing the heavy chain CDR composed of the above-mentioned CDR-H1 (Seq_1), CDR-H2 (Seq_2), and CDR-H3 (Seq_3) is as follows:
[0054] DVQLQESGPGMVKPSQSLSLTCAVTGYSISRGYYWSWIRHFPGNKLEWMGYISNSESVNYNPSLKSRVTITHDTSKNHWFLKLNSVTAADTALYYCARGYECKIPSGLDSWGQGTLVTVSA(Seq_7).
[0055] Light chain variable region:
[0056] The light chain variable region has light chain CDRs composed of CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown below:
[0057] CDR-L1: QASHDIVKALN(Seq_4);
[0058] CDR-L2: YANELAS(Seq_5);
[0059] CDR-L3: QQGYSSPYT(Seq_6).
[0060] The preferred amino acid sequence of the light chain variable region containing the light chain CDR composed of the above-mentioned CDR-L1 (Seq_4), CDR-L2 (Seq_5), and CDR-L3 (Seq_6) is as follows:
[0061] EIQMSQSPSSMSASLGDRITITCQASHDIVKALNWYQQKPGKAPKLLIYYANELASGVPSRFSGSGSGSDYTLTISNLESEDFADYYCQQGYSSPYTFGGRTKLEIK(Seq_8).
[0062] Anti-MPXV-A29L-2
[0063] In some alternative implementations, after immunizing rabbits with monkeypox virus A29L protein, screening and sequence analysis yielded antibodies or antigen-binding fragments thereof that bind to monkeypox virus A29L protein and have the following CDR composition: Anti-MPXV-A29L-2
[0064] Heavy chain variable region:
[0065] The heavy chain variable region has a heavy chain CDR composed of CDR-H1, CDR-H2, and CDR-H3, and the amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 are shown below:
[0066] CDR-H1: DYGMG(Seq_11);
[0067] CDR-H2: YISSGSGSIGYADSVKG(Seq_12);
[0068] CDR-H3: DAGRGGWYGPYYFDY(Seq_13).
[0069] The preferred amino acid sequence of the heavy chain variable region containing the heavy chain CDR composed of the above-mentioned CDR-H1 (Seq_11), CDR-H2 (Seq_12), and CDR-H3 (Seq_13) is as follows:
[0070] EVQLVESGGGVVKPGGSLRLSCAASGFTFDDYGMGWVRQAPEKGLEWVAYISSGSGSIGYADSVKGRFTISRNNAKNTLFLQMTRLRSEDTALYYCAKDAGRGGWYGPYYFDYWGQGTTLTVSS(Seq_17)
[0071] Light chain variable region:
[0072] The light chain variable region has light chain CDRs composed of CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown below:
[0073] CDR-L1:RSSQSLESTNGNMYLN(Seq_14);
[0074] CDR-L2: RVSNRAS(Seq_15);
[0075] CDR-L3: MQALPPYT(Seq_16).
[0076] The preferred amino acid sequence of the light chain variable region containing the light chain CDR composed of the above-mentioned CDR-L1 (Seq_14), CDR-L2 (Seq_15), and CDR-L3 (Seq_16) is as follows:
[0077] DAVMTQTPLSLSVSLGDQASISCRSSQSLESTNGNMYLNWFLQRPNQSPQLLIYRVSNRASGVPDRFSGSGSGTYFTLTISRVEAEDLGVYFCMQALPPYTFGGGTKLEIK(Seq_18).
[0078] Anti-MPXV-A35R-1
[0079] In some alternative implementations, after immunizing rabbits with monkeypox virus A35R protein, screening and sequence analysis yielded antibodies or antigen-binding fragments thereof that bind to monkeypox virus A35R protein, having the following CDR composition: Anti-MPXV-A35R-1.
[0080] Heavy chain variable region:
[0081] The heavy chain variable region has a heavy chain CDR composed of CDR-H1, CDR-H2, and CDR-H3, and the amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 are shown below:
[0082] CDR-H1: SNYWS(Seq_21);
[0083] CDR-H2: YISGSGWNTDYSPSLKS(Seq_22);
[0084] CDR-H3: MKWHCGGSAGYYFDY(Seq_23).
[0085] The preferred amino acid sequence of the heavy chain variable region containing the heavy chain CDR composed of CDR-H1 (Seq_21), CDR-H2 (Seq_22), and CDR-H3 (Seq_23) is as follows:
[0086] QMQLQESGPGLVKPSETLFLTCSILGFSISSNYWSWIRQPPGKPLEWIGYISGSGWNTDYSPSLKSPISITRDTSKNQFFLKLSSVTAADTAVYYCARMKWHCGGRSAGYYFDYWGQGTTLTVSS(Seq_27).
[0087] Light chain variable region:
[0088] The light chain variable region has light chain CDRs composed of CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown below:
[0089] CDR-L1: NTYLH(Seq_24);
[0090] CDR-L2: KVSNRDY(Seq_25);
[0091] CDR-L3: SQGTRLPFT(Seq_26).
[0092] The preferred amino acid sequence of the light chain variable region containing the light chain CDR composed of the above-mentioned CDR-L1 (Seq_24), CDR-L2 (Seq_25), and CDR-L3 (Seq_26) is as follows:
[0093] DVVMTQTPLSLPVSPGDQASVSCRSSQSLVHSNGNTYLHWYQQKPGQSPRLLIYKVSNRDYGVPDRFSGSGSGTDFTLKISRVEPEDVGVYFCSQGTRLPFTFGTGTKLEIK(Seq_28).
[0094] Anti-MPXV-A35R-2
[0095] In some alternative embodiments, after immunizing rabbits with monkeypox virus A35R protein, screening and sequence analysis yielded antibodies or antigen-binding fragments thereof that bind to monkeypox virus A35R protein and have the following CDR composition: Anti-MPXV-A35R-2
[0096] Heavy chain variable region:
[0097] The heavy chain variable region has a heavy chain CDR composed of CDR-H1, CDR-H2, and CDR-H3, and the amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 are shown below:
[0098] CDR-H1: GYWWS(Seq_31);
[0099] CDR-H2: YISYGRTSTNYNPSLKS(Seq_32);
[0100] CDR-H3: FDSNLDSVDV(Seq_33).
[0101] The preferred amino acid sequence of the heavy chain variable region containing the heavy chain CDR composed of the above-mentioned CDR-H1 (Seq_31), CDR-H2 (Seq_32), and CDR-H3 (Seq_33) is as follows:
[0102] DVQLQESGPGMVKPSQTLSLTCAVTGYSITSGYWWSWIRHFPGNKLEWIGYISYGRTSTNYNPSLKSRVIITKDTSKNQFFLKLTSVTAADTAVYFCATFDSNLDSVDVWGQGVLVTVSA(Seq_37).
[0103] Light chain variable region:
[0104] The light chain variable region has light chain CDRs composed of CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown below:
[0105] CDR-L1:RASQSVGSYLA(Seq_34);
[0106] CDR-L2: SASTRAV(Seq_35);
[0107] CDR-L3: VQRRNWYT(Seq_36).
[0108] The preferred amino acid sequence of the light chain variable region containing the light chain CDR composed of the above-mentioned CDR-L1 (Seq_34), CDR-L2 (Seq_35), and CDR-L3 (Seq_36) is as follows:
[0109] TGETTQDPASLSFSLGETATLSCRASQSVGSYLAWYQQKAEQAPRLFIHSASTRAVGVPDRFSGSGSGTDFTLTISSLEHEDVAVYYCVQRRNWYTFGSGSKLEIK(Seq_38).
[0110] Anti-MPXV-M1R-1
[0111] In some alternative embodiments, after immunizing rabbits with monkeypox virus M1R protein, screening and sequence analysis yielded antibodies or their antigen-binding fragments Anti-MPXV-M1R-1 that bind to monkeypox virus M1R protein and have the following CDR composition:
[0112] Heavy chain variable region:
[0113] The heavy chain variable region has a heavy chain CDR composed of CDR-H1, CDR-H2, and CDR-H3, and the amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 are shown below:
[0114] CDR-H1: GYGMH(Seq_41);
[0115] CDR-H2:YISSGSSSTYYADSVKG(Seq_42);
[0116] CDR-H3:GAGSQPDYLDY(Seq_43).
[0117] The preferred amino acid sequence of the heavy chain variable region containing the heavy chain CDR composed of CDR-H1 (Seq_41), CDR-H2 (Seq_42), and CDR-H3 (Seq_43) is as follows:
[0118] EVLLVESGGGLVKPGGSLRLSCVASGFTFGNYGMHWVRQAPGKGLEWVSYISSGSSSTYYADSVKGRFTISKDDAKNTLFLQMTSLRPEDTAVYYCAKGAGSQPDYLDYWGQGTTLTVSS(Seq_47).
[0119] Light chain variable region:
[0120] The light chain variable region has light chain CDRs composed of CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown below:
[0121] CDR-L1: NTYLH(Seq_44);
[0122] CDR-L2: KVSNRFY(Seq_45);
[0123] CDR-L3: SQGTTLPFT(Seq_46).
[0124] The preferred amino acid sequence of the light chain variable region containing the light chain CDR composed of the above-mentioned CDR-L1 (Seq_44), CDR-L2 (Seq_45), and CDR-L3 (Seq_46) is as follows:
[0125] DVVMTQTPLSLPVSPGDQASVSCRSSQSLVHSNGNTYLHWYQQKPGQSPRLLIYKVSNRDYGVPDRFSGSGSGTDFTLKISRVEPEDVGVYFCSQGTRLPFTFGTGTKLEIK(Seq_48).
[0126] Anti-MPXV-M1R-2
[0127] In some alternative embodiments, after immunizing rabbits with monkeypox virus M1R protein, screening and sequence analysis yielded antibodies or their antigen-binding fragments Anti-MPXV-M1R-2 that bind to monkeypox virus M1R protein and have the following CDR composition:
[0128] Heavy chain variable region:
[0129] The heavy chain variable region has a heavy chain CDR composed of CDR-H1, CDR-H2, and CDR-H3, and the amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 are shown below:
[0130] CDR-H1: DHYMH(Seq_51);
[0131] CDR-H2:RISNGGSTTWYADSVKG(Seq_52);
[0132] CDR-H3: TVYDSNHRFDV(Seq_53).
[0133] The preferred amino acid sequence of the heavy chain variable region containing the heavy chain CDR composed of CDR-H1 (Seq_51), CDR-H2 (Seq_52), and CDR-H3 (Seq_53) is as follows:
[0134] EVQLVESGGGLVKPGGSLRLSCAASGFIFSDHYMHWVRQAPEKGLEWVSRISNGGSTTWYADSVKGRFTISRENAKNTLYLQMTSLRTEDTAVYFCARTVYDSNHRFDVWGPGVLVTVYS(Seq_57).
[0135] Light chain variable region:
[0136] The light chain variable region has light chain CDRs composed of CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown below:
[0137] CDR-L1:RSSQSLLHSNGNTYLY(Seq_54);
[0138] CDR-L2: RVSNRAS(Seq_55);
[0139] CDR-L3: MQALAPMYT(Seq_56).
[0140] The preferred amino acid sequence of the light chain variable region containing the light chain CDR composed of the above-mentioned CDR-L1 (Seq_54), CDR-L2 (Seq_55), and CDR-L3 (Seq_56) is as follows:
[0141] DIVMTQAARSLPVTPGESVSISCRSSQSLLHSNGNTYLYWFLQKPGQSPQLLIYRVSNRASGVPDRFSGSGSDTAFTLRISRVEAEDVGVYYCMQALAPMYTFGSGTKVEMK(Seq_58).
[0142] It should be noted that, in this article, the antibodies or antigen-binding fragments of monkeypox virus binding can refer to any one of the following: Anti-MPXV-A29L-1, Anti-MPXV-A29L-2, Anti-MPXV-A35R-1, Anti-MPXV-A35R-2, Anti-MPXV-M1R-1, and Anti-MPXV-M1R-2. The definition and description of the antibodies or antigen-binding fragments of monkeypox virus binding can be understood as the definition and description of any one of the following: Anti-MPXV-A29L-1, Anti-MPXV-A29L-2, Anti-MPXV-A35R-1, Anti-MPXV-A35R-2, Anti-MPXV-M1R-1, and Anti-MPXV-M1R-2.
[0143] As is well known in the art, the binding specificity and affinity of antibodies are primarily determined by the CDR sequence. Based on mature and well-known existing technologies, amino acid sequences in non-CDR regions can be easily altered to obtain variants with similar biological activities. The monoclonal antibody variant of this invention, having a CDR sequence identical to the one described above, possesses similar biological activity because it has the exact same CDR sequence as the antibody that binds to monkeypox virus described in this invention.
[0144] The antigen-binding fragment is an antibody fragment with the same specificity as the parent antibody, and may be, for example, one or more of F(ab')2, Fab', Fab, Fv, scFv, dsFv, bispecific antibodies, and the smallest antibody recognition unit. In addition to the functional fragments mentioned above, any fragment with an extended half-life is also included.
[0145] These functional fragments typically possess the same binding specificity as the antibodies from which they originate. Those skilled in the art, based on the description herein, infer that the antigen-binding fragments of the present invention can be obtained by, for example, enzymatic digestion (including pepsin or papain) and / or by chemical reduction of disulfide bonds.
[0146] The antigen-binding fragment can also be obtained by recombinant genetic techniques known to those skilled in the art or by peptide synthesis, such as an automated peptide synthesizer; or by expressing a gene encoding the above-mentioned functional fragment in a host cell.
[0147] The antibody or antigen-binding fragment of the monkeypox virus provided by this invention, excluding the CDR region, has the remaining sequence sourced from one or more species including, but not limited to, mice, rats, guinea pigs, hamsters, rabbits, ferrets, cats, dogs, goats, sheep, dairy cows, pigs, horses, monkeys, and humans.
[0148] When the antibody molecule binding to monkeypox virus is intact, the antibody type can be, for example, but not limited to, IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD. Given that those skilled in the art are familiar with the CDR region or the variable regions of the light and heavy chains of antibodies, they can use conventional methods in the art to obtain different types of antibodies, such as fusing the variable region gene with the corresponding heavy chain or heavy chain constant region coding gene and expressing the fusion protein in host cells to obtain different types of antibodies.
[0149] In some preferred embodiments, the antibody comprises a sequence of a constant region of any one of rabbit antibody IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.
[0150] In some preferred embodiments, the antibody further includes a heavy chain constant region and a light chain constant region. The amino acid sequence of the heavy chain constant region is preferably as shown in Seq_61; the amino acid sequence of the light chain constant region is preferably as shown in Seq_62.
[0151] According to another aspect of the invention, the invention also provides a biological material, including nucleic acids, a carrier, or a host cell.
[0152] The nucleic acid encodes the antibody or antigen-binding fragment that binds to the monkeypox virus, and the encoding may optionally encode the sense and / or antisense strands. The term "nucleic acid" refers to a polymeric form of nucleotides of any length, including ribonucleotides and / or deoxyribonucleotides. Examples of nucleic acids include, but are not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other naturally occurring, chemically or biochemically modified, non-natural, or derived nucleotide bases.
[0153] The nucleic acid is preferably DNA, and the preferred nucleotide sequence is as follows:
[0154] Encoding the variable region of the Anti-MPXV-A29L-1 heavy chain, the preferred nucleotide sequence is shown in Seq_9;
[0155] Encoding the variable region of the light chain of Anti-MPXV-A29L-1, the preferred nucleotide sequence is shown in Seq_10;
[0156] Encoding the variable region of the Anti-MPXV-A29L-2 heavy chain, the preferred nucleotide sequence is shown in Seq_19;
[0157] Encoding the variable region of the light chain of Anti-MPXV-A29L-2, the preferred nucleotide sequence is shown in Seq_20;
[0158] Encoding the Anti-MPXV-A35R-1 heavy chain variable region, the preferred nucleotide sequence is shown in Seq_29;
[0159] Encoding the variable region of the light chain Anti-MPXV-A35R-1, the preferred nucleotide sequence is shown in Seq_30;
[0160] Encoding the Anti-MPXV-A35R-2 heavy chain variable region, the preferred nucleotide sequence is shown in Seq_39;
[0161] Encoding the variable region of the light chain Anti-MPXV-A35R-2, the preferred nucleotide sequence is shown in Seq_40;
[0162] Encoding the Anti-MPXV-M1R-1 heavy chain variable region, the preferred nucleotide sequence is shown in Seq_49;
[0163] The nucleotide sequence encoding the Anti-MPXV-M1R-1 light chain variable region is preferably shown in Seq_50.
[0164] Vector: The vector contains or integrates the aforementioned nucleic acids. The vector may also include portions encoding other constituent elements, such as, but not limited to, encoding regulatory sequences or marker genes. The vector may be, for example, but not limited to, a prokaryotic expression vector, a eukaryotic expression vector, or an insect expression vector.
[0165] Host cell: The host cell is transformed with the above-mentioned vector to enable the cloning or expression of the vector; or, the host cell's genome integrates the nucleic acid to enable the expression of the antibody or its antigen-binding fragment. The host cell may be, for example, but not limited to, CHO cells or 293T cells.
[0166] According to another aspect of the invention, the invention also provides a composition for tracing, comprising the antibody or antigen-binding fragment thereof that binds to monkeypox virus and a label; the label is linked to the antibody or antigen-binding fragment thereof; or, the label and the antibody or antigen-binding fragment thereof are packaged separately and linked only when needed. The label includes one or more of enzymes, fluorescent molecular markers, fluorescent microspheres, colored microspheres, colloidal gold, biotin, or streptavidin. Examples of enzymes include, but are not limited to, alkaline phosphatase or horseradish peroxidase. Fluorescent molecular markers include, but are not limited to, fluorescent proteins, synthetic small molecules, or polymer dyes. Specific examples include, but are not limited to, Alexa 350, Alexa 405, Alexa 430, Alexa 488, Alexa 555, Alexa 647, AMCA, aminoacridine, BODIPY 630 / 650, BODIPY 650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, 5-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein, 5-carboxy-2′,4′,5′,7′-tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6-carboxytetramethylrhodamine, and Cascade. Blue, Cy2, Cy3, Cy5, Cy7, 6-FAM, Dansyl chloride, Fluorescein, HEX, 6-JOE, NBD (7-nitrobenzo-2-oxa-1,3-diazole), Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, Phthalic acid, Terephthalic acid, Isophthalic acid, Cresol Violet, Cresol Blue Violet, Brilliant Cresol Blue, p-Aminobenzoic acid, Erythrosine, Phthalocyanine, Azocyanine, Anthocyanin, Xanthine, Succinyl fluorescein, Rare earth metal cavitation compounds, Tribispyridyldiamine europium, europium cavitation compounds or chelates, Diamine, Dianthocyanin, La Jolla Blue dye, Allococyanin B. One or more of the following: phycocyanin C, phycocyanin R, thiamine, phycoerythrin, phycoerythrin R, REG, rhodamine green, rhodamine isothiocyanate, rhodamine red, ROX, TAMRA, TET, TRIT (tetramethylrhodamine isothiol), tetramethylrhodamine, and Texas red. Fluorescent microspheres and colored microspheres are each independently selected from products acceptable in the art, such as those derived from commercially available products.
[0167] In some alternative embodiments, the composition for tracing includes (n1) and (n2):
[0168] (n1) Anti-MPXV-A29L-1, Anti-MPXV-A35R-1 or Anti-MPXV-M1R-1;
[0169] (n2) Fluorescent microspheres, colored microspheres or colloidal gold.
[0170] Specific embodiments may include, but are not limited to, Anti-MPXV-A29L-1 and fluorescent microspheres; Anti-MPXV-A29L-1 and colored microspheres; Anti-MPXV-A29L-1 and colloidal gold; Anti-MPXV-A35R-1 and fluorescent microspheres; Anti-MPXV-A35R-1 and colored microspheres; Anti-MPXV-A35R-1 and colloidal gold; Anti-MPXV-M1R-1 and fluorescent microspheres; Anti-MPXV-M1R-1 and colored microspheres; or, Anti-MPXV-M1R-1 and colloidal gold.
[0171] According to another aspect of the present invention, a composition for detecting monkeypox virus is also provided, the composition comprising at least one of the following: an A29L protein pairing antibody or its antigen-binding fragment thereof, an A35R protein pairing antibody or its antigen-binding fragment thereof, and an M1R protein pairing antibody or its antigen-binding fragment thereof: the A29L protein pairing antibody or its antigen-binding fragment thereof is composed of Anti-MPXV-A29L-1 and Anti-MPXV-A29L-2; the A35R protein pairing antibody or its antigen-binding fragment thereof is composed of Anti-MPXV-A35R-1 and Anti-MPXV-A35R-2; and the M1R protein pairing antibody or its antigen-binding fragment thereof is composed of Anti-MPXV-M1R-1 and Anti-MPXV-M1R-2. The two antibodies screened by the present invention that bind to the monkeypox virus A29L, A35R, and M1R proteins respectively can form a pairing antibody. A pairing antibody refers to two antibodies that can simultaneously bind to a single antigen molecule, used for detecting monkeypox virus antigen in a sample using a double-antibody sandwich assay.
[0172] In some preferred embodiments, the composition for detecting monkeypox virus further comprises the above-described tracer composition to provide a detectable signal for the antibody-antigen-antibody complex formed during the detection of monkeypox virus.
[0173] According to another aspect of the present invention, the present invention also provides the use of the above-mentioned antibody or antigen-binding fragment thereof that binds to monkeypox virus, the above-mentioned biological material, the above-mentioned composition for tracing, and the above-mentioned composition for detecting monkeypox virus in the preparation of products for detecting monkeypox virus A29L protein, monkeypox virus A35R protein, monkeypox virus M1R protein, or monkeypox virus. The above-mentioned components can be used directly as detection components or reagents in the product, or as precursors or raw materials for preparing detection components or reagents in the product.
[0174] According to another aspect of the present invention, the present invention also provides a reagent or kit for detecting monkeypox, the reagent or kit comprising the antibody or antigen-binding fragment thereof that binds to the monkeypox virus A29L protein described above, the composition for tracing described above, or the composition described above for detecting monkeypox virus.
[0175] In some preferred embodiments, the kit includes test strips selected from colloidal gold test strips, fluorescent microsphere immunochromatographic test strips, or color microsphere immunochromatographic test strips. The test strips employ a double-antibody sandwich immunochromatography method, embedding labeled anti-Anti-MPXV-A29L-1 / 2, Anti-MPXV-A35R-1 / 2, or Anti-MPXV-M1R-1 / 2 on the binding pad, and coating the detection line (T) with anti-monkeypox virus Anti-MPXV-A29L-2 / 1, Anti-MPXV-A35R-2 / 1, or Anti-MPXV-M1R-2 / 1.
[0176] In some preferred embodiments, the antibody labeled with the marker in the test strip is selected from Anti-MPXV-A29L-1, Anti-MPXV-A35R-1, or Anti-MPXV-M1R-1; the antibody coated on the detection area of the test strip is selected from Anti-MPXV-A29L-2, Anti-MPXV-A35R-2, or Anti-MPXV-M1R-2, and the antibody coated on the detection area is paired with the antibody labeled with the marker; wherein the working concentration of Anti-MPXV-A29L-2, Anti-MPXV-A35R-2, or Anti-MPXV-M1R-2 is preferably 0.8 to 2.5 mg / mL, for example, but not limited to 0.8, 1, 1.5, 2, or 2.5 mg / mL. When the test strip is a colloidal gold test strip or a colored microsphere immunochromatographic test strip, the working concentration of Anti-MPXV-A29L-1, Anti-MPXV-A35R-1 or Anti-MPXV-M1R-1 is preferably 20 to 50 μg / mL, for example, but not limited to 20, 25, 30, 35, 40, 45 or 50 μg / mL, preferably 30 μg / mL.
[0177] In some optional embodiments, the kit further includes a sample dilution reagent comprising a buffer, a surfactant, and a blocking protein; the buffer comprises one or more of carbonates, citrates, phosphates, borates, and tris(hydroxymethyl)aminomethane; the surfactant comprises one or more of Tween-20, Tween-80, CHAPS, Brij35, Brij23, Triton-X100, SDS, sodium lauroyl sarcosinate, etc.; and the blocking protein comprises BSA or sodium caseinate.
[0178] According to another aspect of the invention, the invention also provides a medicament for the prevention or treatment of monkeypox, the medicament comprising the antibody or antigen-binding fragment thereof that binds to the monkeypox virus, or the aforementioned biological material; and pharmaceutically optional excipients.
[0179] Antibodies or antigen-binding fragments thereof that bind to monkeypox virus, including but not limited to one or more of Anti-MPXV-A29L-1, Anti-MPXV-A29L-2, Anti-MPXV-A35R-1, Anti-MPXV-A35R-2, Anti-MPXV-M1R-1, and Anti-MPXV-M1R-2. Antibodies or antigen-binding fragments thereof that bind to the monkeypox virus A29L protein may optionally serve as a primary or secondary functional component for the prevention or treatment of monkeypox. It is understood that the drug may also contain other active ingredients, such as antiviral drugs.
[0180] Examples of excipients include, but are not limited to, solvents, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flow aids, anti-caking agents, flavoring agents, antibacterial agents, suspending agents, coating agents, film-forming agents, fragrances, thickeners, anti-adhesion agents, antioxidants, antioxidant synergists, chelating agents, pH adjusters, adsorbents, plasticizers, surfactants, thickeners, encapsulating agents, protectants, humectants, softeners, absorbents, diluents, release regulators, pressure-sensitive adhesives, hardeners, empty capsules, matrix and drug carrier materials, or one or more of these.
[0181] The technical solution and beneficial effects of the present invention will be further described below with reference to preferred embodiments.
[0182] Example 1
[0183] Acquisition of recombinant antigens: Based on data on monkeypox virus published in the NCBI database, recombinant antigens of A29L, A35R, and M1R proteins were commercially synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0184] Example 2
[0185] Animal immunity:
[0186] Add 30 μg of each of the three antigens, A29L, A35R, and M1R, to 0.5 mL of autoclaved physiological saline and mix thoroughly using a micro vortex mixer. Mix 0.5 mL of Freund's complete adjuvant with each antigen in equal volumes and emulsify thoroughly. Select New Zealand white rabbits of appropriate age and weighing approximately 1.5 kg and house them in a standard animal facility for 3 days. If no abnormalities are observed, administer immunization via subcutaneous injection at multiple sites. Three days before immunization, collect ear blood from the New Zealand white rabbits and separate the serum as a negative control.
[0187] Booster immunizations were administered every other week, for a total of six immunizations. Starting with the third immunization, 200–500 μL of blood from the marginal ear vein of New Zealand rabbits was collected one week after immunization to determine its titer and affinity. The spleen was harvested after the final immunization for the preparation of hybridoma cells.
[0188] The method for determining potency is as follows:
[0189] (1) Coating: Three recombinant antigens were used as coating antigens, with a coating concentration of 100 ng / well, and the coating was carried out at 37°C for 2 h.
[0190] (2) Blocking: Add blocking solution prepared with 3% BSA, incubate at 37°C for 1 hour, discard the liquid, and dry for later use.
[0191] (3) Antibody serum incubation: After serial dilution of the antibody serum, add 100 μL to each well of the ELISA plate and incubate at 37°C for 1 h.
[0192] (4) Enzyme-labeled antibody reaction: Wash three times with PBST, each time for 3 min. Then use HRP-labeled goat anti-rabbit IgG as enzyme-labeled antibody, dilute 1:5000, add 100 μL to each well, incubate at 37℃ for 1 h, then wash three times with PBST, each time for 40 s.
[0193] (5) Color development: Add 100 μL of TMB to each well and let stand. Incubate at 37°C for 15 min to develop color.
[0194] (6) Termination of reaction and reading: Add 50 μL of stop solution to each well to end the reaction, and read the OD450 value using an ELISA reader. Evaluate the antibody titer based on the reading results.
[0195] Example 3
[0196] Preparation and screening of hybridoma cells:
[0197] The prepared rabbit antiserum was tested for potency. If the potency was qualified, rabbit spleen was used for cell fusion to prepare a monoclonal hybridoma cell line. The method was as follows: Immunized New Zealand rabbits were sacrificed, and the spleen was removed under aseptic conditions. The spleen was washed once with cell culture medium, then crushed and passed through a stainless steel sieve. The resulting cells were centrifuged and washed twice with cell culture medium. SP2 / 0 myeloma cells in the logarithmic growth phase were mixed with spleen cells, washed once with cell culture medium without fetal bovine serum, centrifuged, and the supernatant was discarded. Polyethylene glycol solution was added, and the mixture was incubated at 37°C for 90 seconds. The reaction was terminated with cell culture medium without fetal bovine serum (FBS), followed by centrifugation. Cells were resuspended in HAT selection medium containing 20% FBS and added to 96-well plates, where they were cultured at 37°C and 5.0% CO2. Cells in good growth condition in the 96-well plates were diluted with cell culture medium to 1–3 cells / mL and added to the plates. The plates were then incubated at 37°C and 5.0% CO2. Each cell line was numbered, and cell lines showing positive results in the culture supernatant were selected for further expansion to obtain hybridoma cell lines. The obtained hybridoma cells were screened using ELISA. Cell growth was observed on day 5 post-fusion, and the titer of the cell culture supernatant was detected using indirect ELISA on days 10–14. The hybridoma cells with the highest titer were expanded until 100% positivity was achieved, and the resulting hybridoma cell lines were cryopreserved in liquid nitrogen for later use.
[0198] Example 4
[0199] Isolation of antibody variable region genes from hybridoma cells using RT-PCR:
[0200] After homogenizing the hybridoma cells screened in Example 3, RNA was extracted by adding cell lysis buffer. RNA was precipitated from the aqueous phase with isopropanol, centrifuged, washed to remove impurities, resuspended, and reverse transcribed to obtain cDNA. PCR was performed using specific primers from New Zealand rabbits, with hybridoma cell cDNA as a template, to amplify the variable region genes of the heavy and light chains of the antibody. A 50 μL system contained 5 μL of cDNA, HotStarTaq Plus enzyme, dNTPs, and 0.5 μM of specific primers. PCR amplification was performed under the following conditions: pre-denaturation at 94℃ for 5 min; 35 cycles of 94℃ for 30 s, 55℃ for 30 s, and 72℃ for 50 s; 72℃ for 7 min. The obtained PCR product was identified by 1% agarose gel electrophoresis, the target fragment was recovered, and sequenced. The sequencing results were compared with the IMGT database (http: / / www.imgt.org / IMGT_vquest / vquest) to obtain the following variable region gene fragment of the antibody.
[0201] Rabbits were immunized with the A29L antigen, and antibodies Anti-MPXV-A29L-1 and Anti-MPXV-A29L-2 were obtained through screening.
[0202] The amino acid sequences of the three heavy chain CDRs of antibody Anti-MPXV-A29L-1 are shown in Seq_1, Seq_2 and Seq_3, respectively; the amino acid sequence of the variable region of the heavy chain is shown in Seq_7; and the nucleotide sequence is shown in Seq_9. The amino acid sequences of the three light chain CDRs are shown in Seq_4, Seq_5 and Seq_6, respectively; the amino acid sequence of the variable region of the light chain is shown in Seq_8; and the nucleotide sequence is shown in Seq_10.
[0203] The amino acid sequences of the three heavy chain CDRs of antibody Anti-MPXV-A29L-2 are shown in Seq_11, Seq_12 and Seq_13, respectively; the amino acid sequence of the variable region of the heavy chain is shown in Seq_17; and the nucleotide sequence is shown in Seq_19. The amino acid sequences of the three light chain CDRs are shown in Seq_14, Seq_15 and Seq_16, respectively; the amino acid sequence of the variable region of the light chain is shown in Seq_18; and the nucleotide sequence is shown in Seq_20.
[0204] Rabbits were immunized with the A35R antigen, and antibodies Anti-MPXV-A35R-1 and Anti-MPXV-A35R-2 were obtained through screening.
[0205] The amino acid sequences of the three heavy chain CDRs of antibody Anti-MPXV-A35R-1 are shown in Seq_21, Seq_22 and Seq_23, respectively; the amino acid sequence of the variable region of the heavy chain is shown in Seq_27; and the nucleotide sequence is shown in Seq_29. The amino acid sequences of the three light chain CDRs are shown in Seq_24, Seq_25 and Seq_26, respectively; the amino acid sequence of the variable region of the light chain is shown in Seq_28; and the nucleotide sequence is shown in Seq_30.
[0206] The amino acid sequences of the three heavy chain CDRs of antibody Anti-MPXV-A35R-2 are shown in Seq_31, Seq_32 and Seq_33, respectively; the amino acid sequence of the variable region of the heavy chain is shown in Seq_37; and the nucleotide sequence is shown in Seq_39. The amino acid sequences of the three light chain CDRs are shown in Seq_34, Seq_35 and Seq_36, respectively; the amino acid sequence of the variable region of the light chain is shown in Seq_38; and the nucleotide sequence is shown in Seq_40.
[0207] Rabbits were immunized with the A35R antigen, and antibodies Anti-MPXV-M1R-1 and Anti-MPXV-M1R-2 were obtained through screening.
[0208] The amino acid sequences of the three heavy chain CDRs of antibody Anti-MPXV-A29L-1 are shown in Seq_41, Seq_42, and Seq_43, respectively; the amino acid sequence of the variable region of the heavy chain is shown in Seq_47; and the nucleotide sequence is shown in Seq_49. The amino acid sequences of the three light chain CDRs are shown in Seq_44, Seq_45, and Seq_46, respectively; the amino acid sequence of the variable region of the light chain is shown in Seq_48; and the nucleotide sequence is shown in Seq_50.
[0209] The amino acid sequences of the three heavy chain CDRs of antibody Anti-MPXV-M1R-2 are shown in Seq_51, Seq_52 and Seq_53, respectively; the amino acid sequence of the variable region of the heavy chain is shown in Seq_57; and the nucleotide sequence is shown in Seq_59. The amino acid sequences of the three light chain CDRs are shown in Seq_54, Seq_55 and Seq_56, respectively; the amino acid sequence of the variable region of the light chain is shown in Seq_58; and the nucleotide sequence is shown in Seq_60.
[0210] Example 5
[0211] Homologous recombination arms were added to both ends of the antibody heavy chain variable region gene and the light chain variable region gene using homologous recombination primers. The expression plasmids containing the rabbit antibody heavy chain IgG1 constant region and the expression plasmid containing the rabbit antibody light chain IgG1 constant region were linearized using double enzyme digestion, generating homologous recombination arms. The amino acid sequence of the heavy chain constant region is shown in Seq_61, and the nucleotide sequence is shown in Seq_63; the amino acid sequence of the light chain constant region is shown in Seq_62, and the nucleotide sequence is shown in Seq_64. The variable region gene fragments with added homologous recombination arms and the linearized plasmids were ligated together by homologous recombination to construct complete light chain expression vectors and heavy chain expression vectors. The recombination products were transformed into TOP10 E. coli competent cells for plasmid amplification.
[0212] The obtained monoclonal antibody heavy and light chain expression plasmids were added to Opti-Mem transfection medium at a 1:1 ratio. After thorough mixing, PEI transfection reagent (4 times the mass of DNA) was added. After mixing, the mixture was incubated at room temperature in the dark for 30 min, and then added to 293T cells. After incubation for 6 h, the transfection system was removed, and FreeStyle™ 293 expression medium was added. The expressed antibody supernatant was purified using the AKTA protein purification system and the affinity purification (Protein A) method to obtain monoclonal antibodies. The specific steps were as follows: (1) The expressed antibody supernatant was centrifuged at 2500×g at room temperature for 10 min to remove the precipitate; (2) The affinity purification column containing Protein A was thoroughly washed with 10 times the volume of binding buffer; (3) The expression supernatant was passed through the purification column at a flow rate of 5 mL / min; (4) The purification column was thoroughly washed with 20 times the volume of binding buffer; (5) 0.1M The purification column was eluted with citrate buffer at pH 3.0-3.5 until the elution peak reached equilibrium. The pH was then adjusted to 7.0 with 1M Tris-HCl buffer at pH 9.0. (6) The purified monoclonal antibody was concentrated using a centrifugal column. PBS was used as the antibody storage buffer. Finally, the concentration of the concentrated antibody was determined using the BSA protein concentration detection method.
[0213] Example 6
[0214] Molecular weight determination:
[0215] A 12% SDS-PAGE gel was prepared using standard methods. Different antibodies were loaded at 5 μg per sample. Electrophoresis was performed using protein molecular weight standards as a reference. The results showed that the six anti-monkeypox virus monoclonal antibodies exhibited two characteristic bands of approximately 25 KD and 55 KD, representing the light and heavy chains of IgG, respectively. The electrophoresis results are shown below. Figure 1 As shown, the antibody content of all bands was above 90% after scanning and analysis.
[0216] Figure 1 The lanes 1-6 in the middle swimming pool are as follows: 1: Anti-MPXV-A29L-1; 2: Anti-MPXV-A29L-2; 3: Anti-MPXV-A35R-1; 4: Anti-MPXV-A35R-2; 5: Anti-MPXV-M1R-1; 6: Anti-MPXV-M1R-2.
[0217] Example 7
[0218] This embodiment provides a fluorescent microsphere immunochromatographic test strip, which is prepared according to the following method:
[0219] (1) Antibody labeling of fluorescent microspheres: 1 mL of 1% carboxyl fluorescent microspheres were added to 9 mL of MES buffer, followed by 25 μL of LEDC solution (10 mg / mL) and 25 μL of NHS solution (10 mg / mL). The mixture was incubated at room temperature with shaking for 30 min, and the precipitate was collected by centrifugation. HEPES reconstitution solution was added, and the mixture was sonicated until homogeneous. Then, 1 mL of 1 mg / mL Anti-MPXV-A29L-1 was added, and the mixture was incubated at room temperature with shaking for 120 min, and the precipitate was collected by centrifugation. 1 mL of blocking buffer (5% BSA) was added, and the mixture was incubated at room temperature with shaking for 120 min. The microsphere precipitate was collected by centrifugation and reconstituted with the reconstitution solution.
[0220] Add 1 mL of 1% carboxyl fluorescent microspheres to 9 mL of MES buffer, then add 25 μL of EDC solution (10 mg / mL) and 25 μL of NHS solution (10 mg / mL). Incubate at room temperature with shaking for 30 min, then centrifuge to collect the precipitate. Add HEPES reconstitution solution, sonicate to disperse evenly, then add 1 mL of 1 mg / mL chicken IgY. Incubate at room temperature with shaking for 120 min, then centrifuge to collect the precipitate. Add 1 mL of blocking solution (5% BSA), and incubate at room temperature with shaking for 120 min. Centrifuge to collect the microsphere precipitate and reconstitute with the reconstitution solution.
[0221] (2) Preparation of fluorescent pads: The labeled fluorescent microspheres were diluted with a microsphere reconstitution solution and mixed at a ratio of 5:1. The fluorescent pads were then sprayed using a gold spraying spectrometer at a spraying density of 3 μL / cm and a spraying spacing of 6 mm. After spraying, the pads were dried at 37°C and low humidity (<30%) for 2 hours.
[0222] (3) NC membrane coating C line (control line) and T line (detection line): T line uses Anti-MPXV-A29L-2 with a concentration of 1.5 mg / mL, C line uses goat anti-chicken IgY antibody with a concentration of 1 mg / mL, 1 μL / cm for streaking, and after completion, place in 37℃ low humidity (<30%) for drying for 24h.
[0223] (4) Sample pad treatment: The sample pad treatment solution consists of buffer salts, slow-release agents, solubilizers, and sealing agents. The specific formula is 20 mM Tris, 1% BSA, 0.5% Tween 20, and 2% sucrose. Apply per 20 cm... 2 Use 1 mL of sample processing solution for treatment. After thorough treatment, place the sample in a 37°C, low humidity (<30%) environment for 2 hours to dry.
[0224] (5) Test strip assembly: Attach the NC film, absorbent pad, fluorescent pad, and sample pad sequentially to the PVC board. The absorbent pad and fluorescent pad should each overlap the NC film by 1-2 mm, and the sample pad should overlap the fluorescent pad by 1-2 mm. After assembly, cut the test strip to a width of 4±0.4 mm and insert it into a cartridge. Place the cartridge and desiccant together in an aluminum foil bag and seal it. Label and box to obtain the finished test strip test card.
[0225] Example 8
[0226] This embodiment provides a fluorescent microsphere immunochromatographic test strip, which differs from Example 7 only in that Anti-MPXV-A29L-1 in the fluorescent microsphere-labeled antibody is replaced with Anti-MPXV-A35R-1; the T line is coated with Anti-MPXV-A29L-2 at a concentration of 1.2 mg / mL.
[0227] Example 9
[0228] This embodiment provides a fluorescent microsphere immunochromatographic test strip, which differs from Example 7 only in that Anti-MPXV-A29L-1 in the fluorescent microsphere-labeled antibody is replaced with Anti-MPXV-M1R-1; the T line is coated with Anti-MPXV-M1R-2 at a concentration of 2.1 mg / mL.
[0229] Examples 10-12
[0230] Examples 10-12 each provide a monkeypox virus detection kit, comprising the fluorescent microsphere immunochromatographic test strips provided in Examples 7-9, and further comprising a sample dilution reagent, wherein the sample dilution reagent comprises:
[0231] The sample diluent matrix is 0.2M Tris buffer, and also contains 0.2% Tween-20, 0.1% BSA, 1% PVP, 0.5% surfactant S9, 0.2% sodium caseinate, 0.5% trehalose and 0.2% surfactant S13.
[0232] Example 13
[0233] This embodiment provides a colloidal gold test strip, which is prepared according to the following method:
[0234] (1) Colloidal gold-labeled antibody:
[0235] (1.1) The pH of the gold solution with a particle size of 60 nm was adjusted to 8.0 using 0.1 mol / L K2CO3.
[0236] (1.2) Take 1 mL of the pH-adjusted solution above, add 30 μg of Anti-MPXV-A29L-1 and 5 μg of chicken IgY, react at room temperature for 1 h, centrifuge and discard the supernatant.
[0237] (1.3) Add 1 mL of 20% BSA and block for 2 h, then centrifuge and discard the supernatant.
[0238] (1.4) After redissolving in 100 μl of colloidal gold reconstitution solution at pH 8.0, dilute with the reconstitution solution at a ratio of 15%.
[0239] (2) Preparation of gold pads: The diluted solution of the labeled colloidal gold antibody complex was used to spray fluorescent pads using a gold spraying apparatus at a spraying density of 7.5 μL / cm and a spraying spacing of 6 mm. After spraying, the pads were dried at 37°C and low humidity (<30%) for 2 hours.
[0240] (3) Sample pad preparation: The sample pad treatment solution consists of buffer salts, slow-release agents, solubilizers, and sealing agents. The specific formula is 20 mM Tris, 1% BSA, 0.5% Tween 20, and 2% sucrose. Apply according to a 20 cm... 2 Use 1 mL of sample processing solution for treatment. After thorough treatment, place the sample in a 37°C, low humidity (<30%) environment for 2 hours to dry.
[0241] (4) C / T line coating: T line was coated with Anti-MPXV-A29L-2 at a concentration of 1.5 mg / mL, and C line was coated with goat anti-chicken IgY antibody at a concentration of 1 mg / mL. The lines were streaked at 1 μL / cm and then dried at 37℃ with low humidity (<30%) for 24 h.
[0242] (5) Test strip assembly: Attach the NC film, absorbent pad, gold pad, and sample pad sequentially to the PVC board. The absorbent pad and gold pad each overlap the NC film by 1-2 mm, and the sample pad overlaps the fluorescent pad by 1-2 mm. After assembly, cut the test strip to a width of 4±0.4 mm and insert it into a cartridge. Place the cartridge and desiccant together in an aluminum foil bag. Label and box to obtain the finished test strip.
[0243] Example 14
[0244] This embodiment provides a colloidal gold test strip, which differs from Example 13 only in that Anti-MPXV-A29L-1 in the colloidal gold-labeled antibody is replaced with Anti-MPXV-A35R-1; the T line is coated with Anti-MPXV-A29L-2 at a concentration of 1.2 mg / mL.
[0245] Example 15
[0246] This embodiment provides a colloidal gold test strip, which differs from Example 13 only in that Anti-MPXV-A29L-1 in the colloidal gold-labeled antibody is replaced with Anti-MPXV-M1R-1; the T line is coated with Anti-MPXV-M1R-2 at a concentration of 2.1 mg / mL.
[0247] Examples 16-18
[0248] Examples 16-18 each provide a monkeypox virus detection kit, comprising the colloidal gold immunochromatographic test strips provided in Examples 13-15, and a sample dilution reagent, wherein the sample dilution reagent comprises: a matrix of 20mM borate-borax buffer (pH 8.5), and further comprising 0.5% Tween-20, 0.2% BSA, 0.1% Brij35, 0.2% Triton-X100 and 0.3% sodium casein.
[0249] Example 19
[0250] This embodiment provides a colored microsphere test strip, which is prepared in the same way as in Embodiment 13, except that the colloidal gold is replaced with colored microspheres.
[0251] Example 20
[0252] This embodiment provides a colored microsphere test strip, which is prepared in the same way as in Embodiment 14, except that the colloidal gold is replaced with colored microspheres.
[0253] Example 21
[0254] This embodiment provides a colored microsphere test strip, which is prepared in the same way as in Embodiment 15, except that the colloidal gold is replaced with colored microspheres.
[0255] Examples 22-24
[0256] Examples 22-24 each provide a monkeypox virus detection kit, comprising the color microsphere immunochromatographic test strips provided in Examples 19-21, and a sample dilution reagent, wherein the sample dilution reagent comprises: a matrix of 20mM borate-borax buffer (pH 8.5), and further comprising 0.5% Tween-20, 0.2% BSA, 0.1% Brij35, 0.2% Triton-X100 and 0.3% sodium casein.
[0257] Example 1
[0258] The affinity activity (titer) of monoclonal antibodies to antigens was detected by ELISA. The main steps are as follows: (1) A29L antigen, A35R antigen and M1R antigen were diluted with PBS to 1 ng / μL, and 100 μL was added to each well of a 96-well microplate. The plate was coated at 37°C for 2 h. (2) The supernatant was discarded, and the plate was washed 3 times with 0.01M PBST. Blocking buffer containing 3% BSA was prepared with PBST and 100 μL was added to each well. The plate was blocked at 37°C for 2 h. (3) The supernatant was discarded, and the plate was washed 5 times with PBST. The purified and concentrated antibody was then subjected to gradient dilution. (3) Dilute the antibody concentration from 1:1000 to 1:2560000 and add 100 μL to each well. Incubate at 37°C for 1 h. (4) Discard the antibody diluent, wash 6 times with PBST, dilute goat anti-rabbit IgG-HRP with 1:5000 blocking buffer, add 100 μL to each well, and incubate at 37°C for 1 h. (5) Discard the secondary antibody diluent, wash 6 times with PBST, add TMB, 100 μL / well, and incubate at 37°C for 15 min in the dark. (6) Add 50 μL of 1M dilute sulfuric acid to each well to stop the reaction, and measure the absorbance at 450 nm. The results are as follows. Figure 2 As shown, the screened monoclonal antibodies have strong binding ability to A29L antigen, A35R antigen and M1R antigen, and the titer for the three antigens reaches 1:1280000 (OD value > 0.5).
[0259] The results of the affinity activity detection of monoclonal antibodies against monkeypox virus are shown in Tables 1 to 3. Under the condition that the OD value remains unchanged, the higher the dilution factor of the monoclonal antibody, the stronger the antigen-antibody binding ability.
[0260] As shown in Table 1, the screened Anti-MPXV-A29L-1 and Anti-MPXV-A29L-2 exhibited strong binding ability to the A29L antigen, with a titer of 1:1,280,000 (OD value > 0.5). Figure 2 and Figure 3 The graph shows the results of the potency determination of Anti-MPXV-A29L-1 and Anti-MPXV-A29L-2.
[0261] Table 1. Anti-MPXV-A29L potency test results
[0262]
[0263]
[0264] As shown in Table 2, the screened Anti-MPXV-A35R-1 and Anti-MPXV-A35R-2 exhibit strong binding ability to the A35R antigen, with titers exceeding 1:1,280,000 (OD value > 0.5). Figure 4 and Figure 5 The graph shows the results of potency determination for Anti-MPXV-A35R-1 and Anti-MPXV-A35R-2.
[0265] Table 2. Anti-MPXV-A35R potency test results
[0266]
[0267] As shown in Table 3, the screened Anti-MPXV-M1R-1 and Anti-MPXV-M1R-2 exhibit strong binding ability to the M1R antigen, with titers exceeding 1:1280000 (OD value > 0.5). Figure 6 and Figure 7 The graph shows the results of the potency determination of Anti-MPXV-M1R-1 and Anti-MPXV-M1R-2.
[0268] Table 3 Results of M1R monoclonal antibody titer test
[0269]
[0270] Example 2
[0271] The monkeypox virus detection kits provided in Examples 10-12 were used to detect the samples. The detection card was placed on a clean and flat surface, and 90-100 μL of the processed sample was added to the sample dispensing end of the detection card.
[0272] Import the standard curve of the test strip. After 15 minutes, use a fluorescence immunoassay analyzer to scan the detection area to obtain the fluorescence signal. The concentration value corresponding to the monkeypox virus antigen will be displayed after the detection. The measurement results are as follows.
[0273] Table 4. Test results of diluent samples
[0274]
[0275]
[0276] Table 5 Results of positive recombinant antigen tests
[0277]
[0278] Example 3
[0279] The monkeypox virus detection kits provided in Examples 16-18 were used to detect the samples (colloidal gold method). The test card from the kit was placed on a clean, flat surface, and 90-100 μL of the prepared recombinant antigen sample was added to the sample application end of the test card. After 10 minutes, the test card window was observed; two lines were positive, and only one C line was negative. The test results are as follows: The results show that the antigen concordance rate of the three pairs of monoclonal antibody-assembled test strips was 100%.
[0280] Table 6 Results of Positive Recombinant Antigen Tests
[0281]
[0282] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. An antibody or antigen-binding fragment thereof that binds to a monkeypox virus, characterized in that, The antibody or its antigen-binding fragment has a heavy chain variable region and a light chain variable region; The heavy chain variable region includes three complementary determinant regions CDR-H1, CDR-H2 and CDR-H3; The light chain variable region includes three complementary determinant regions CDR-L1, CDR-L2 and CDR-L3; The antibody or its antigen-binding fragment is: Antibodies or antigen-binding fragments of monkeypox virus A29L protein, such as Anti-MPXV-A29L-1 or Anti-MPXV-A29L-2, that bind to the monkeypox virus A29L protein; The amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of Anti-MPXV-A29L-1 are shown in Seq_1, Seq_2 and Seq_3, respectively; the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 are shown in Seq_4, Seq_5 and Seq_6, respectively. The amino acid sequences of CDR-H1, CDR-H2, and CDR-H3 of Anti-MPXV-A29L-2 are shown in Seq_11, Seq_12, and Seq_13, respectively; the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are shown in Seq_14, Seq_15, and Seq_16, respectively.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein, The amino acid sequence of the heavy chain variable region of Anti-MPXV-A29L-1 is shown in Seq_7, and the amino acid sequence of the light chain variable region is shown in Seq_8. Alternatively, the amino acid sequence of the heavy chain variable region of Anti-MPXV-A29L-2 is shown in Seq_17, and the amino acid sequence of the light chain variable region is shown in Seq_18.
3. The antibody or antigen-binding fragment thereof of claim 1 or 2, wherein, The antibody type is IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.
4. The antibody or antigen-binding fragment thereof of claim 1 or 2, wherein, The antibody or its antigen-binding fragment, excluding the CDR region, has a sequence derived from rabbits.
5. The antibody or antigen-binding fragment thereof of claim 1 or 2, wherein, The antibody also includes a heavy chain constant region and a light chain constant region.
6. The antibody or its antigen-binding fragment according to claim 1 or 2, characterized in that, The antibody comprises a sequence of a constant region of any one of rabbit antibody IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.
7. The antibody or its antigen-binding fragment according to claim 5, characterized in that, The amino acid sequence of the heavy chain constant region of the antibody is shown in Seq_61. The amino acid sequence of the constant region of the light chain of the antibody is shown in Seq_62.
8. The antibody or its antigen-binding fragment according to claim 1 or 2, characterized in that, The antigen-binding fragment is selected from one of F(ab')2, Fab', Fab and Fv.
9. A biomaterial, characterized in that, Including nucleic acids, vectors, or host cells; The nucleic acid encodes the antibody or antigen-binding fragment thereof as described in any one of claims 1-8; the nucleic acid comprises DNA or RNA; The carrier contains the nucleic acid; The host cell is transformed by the vector; or, the host cell's genome contains the nucleic acid.
10. The biomaterial according to claim 9, characterized in that, The DNA encodes the Anti-MPXV-A29L-1 heavy chain variable region, and its nucleotide sequence is shown in Seq_9.
11. The biomaterial according to claim 9, characterized in that, The DNA encodes the variable region of the Anti-MPXV-A29L-1 light chain, and its nucleotide sequence is shown in Seq_10.
12. The biomaterial according to claim 9, characterized in that, The DNA encodes the Anti-MPXV-A29L-2 heavy chain variable region, and its nucleotide sequence is shown in Seq_19.
13. The biomaterial according to claim 9, characterized in that, The DNA encodes the variable region of the Anti-MPXV-A29L-2 light chain, and its nucleotide sequence is shown in Seq_20.
14. A composition for tracer, characterized in that, It comprises the antibody or its antigen-binding fragment and marker as described in any one of claims 1-8.
15. The composition for tracing according to claim 14, characterized in that, The labeling material includes one or more of enzymes, fluorescent molecular labels, fluorescent microspheres, colored microspheres, colloidal gold, biotin, or streptavidin.
16. The composition for tracing according to claim 14, characterized in that, The composition comprises (n1) and (n2): (n1) Anti-MPXV-A29L-1; (n2) Fluorescent microspheres, colored microspheres or colloidal gold.
17. A composition for detecting monkeypox virus, characterized in that, Contains A29L protein-pairing antibodies or their antigen-binding fragments; The A29L protein-pairing antibody or its antigen-binding fragment is composed of Anti-MPXV-A29L-1 and Anti-MPXV-A29L-2 as described in any one of claims 1-8.
18. The composition for detecting monkeypox virus according to claim 17, characterized in that, The composition for detecting monkeypox virus further comprises the tracing composition according to any one of claims 14-16.
19. The use of the antibody or antigen-binding fragment thereof that binds to monkeypox virus according to any one of claims 1-8, the biological material according to any one of claims 9-13, the composition for tracing according to any one of claims 14-16, and the composition for detecting monkeypox virus according to claim 17 or 18 in the preparation of a product for detecting monkeypox virus A29L protein or monkeypox virus.
20. A reagent or kit for detecting monkeypox virus, characterized in that, The composition comprises the antibody or antigen-binding fragment thereof that binds to monkeypox virus as described in any one of claims 1-8, the composition for tracing as described in any one of claims 14-16, or the composition for detecting monkeypox virus as described in claim 17 or 18.
21. The reagent or kit for detecting monkeypox virus according to claim 20, characterized in that, The kit includes test strips; the test strips are selected from colloidal gold test strips, fluorescent microsphere immunochromatographic test strips, or color microsphere immunochromatographic test strips.
22. The reagent or kit for monkeypox virus detection according to claim 21, characterized in that, In the test strip, the antibody labeled with the marker is selected from Anti-MPXV-A29L-1; the antibody coated in the detection area of the test strip is selected from Anti-MPXV-A29L-2, and the antibody coated in the detection area is paired with the antibody labeled with the marker.
23. The reagent or kit for detecting monkeypox virus according to claim 22, characterized in that, The working concentration of Anti-MPXV-A29L-2 is 0.8~2.5 mg / mL; The test strip is a colloidal gold test strip or a colored microsphere immunochromatographic test strip, and the working concentration of Anti-MPXV-A29L-1 is 20~50 μg / mL.
24. The reagent or kit for detecting monkeypox virus according to any one of claims 20-23, characterized in that, The kit includes a sample dilution reagent.
25. The reagent or kit for monkeypox virus detection according to claim 24, characterized in that, The sample dilution reagent includes buffer substances, surfactants, and blocking proteins; The buffering substance includes one or more of carbonates, citrates, phosphates, borates, and tris(hydroxymethyl)aminomethane; The surfactant includes one or more of Tween-20, Tween-80, CHAPS, Brij35, Brij23, Triton-X100, SDS, and sodium lauroyl sarcosinate. The blocking protein includes BSA or casein sodium.
Citation Information
Patent Citations
Detection kit for monkey pox virus antigen and preparation method thereof
CN114755418A
Specific fusion protein antigen of monkey pox virus as well as preparation method and application of specific fusion protein antigen
CN115043948A
